Solid Biosciences is engaged in curing Duchenne muscular dystrophy (Duchenne), a genetic muscle-wasting disease predominantly affecting boys. SGT-001 is Co.'s primary gene transfer candidate. SGT-001 is designed to address the underlying genetic cause of Duchenne by delivering a synthetic transgene that produces dystrophin-like protein that is only expressed in muscles of the body, including cardiac and respiratory muscles. Co.'s complementary disease-modifying therapy, Anti-LTBP4, is a monoclonal antibody for reducing fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. Co. is also developing wearable assistive devices. Co. refers to these devices as the Solid Suit. The SLDB stock yearly return is shown above.
The yearly return on the SLDB stock yearly return page and across the coverage universe of our site,
is a measure of the annual return over the calendar year 2021 for the given stock.
When performing this calculation it is important to factor in dividends, because a financial instrument's annual return is
more than just the change in price if that instrument pays a dividend or coupon.
One way to factor dividends into the return is simply to count them as cash — we don't do
that here. Instead, our website aims to empower investors
by performing the SLDB annual return calculation with any dividends reinvested as applicable (on ex-dates).
|